VESALIUS-CV results show evolocumab reduced the risk of first cardiovascular events among patients with atherosclerosis or diabetes and without a previous #cvMI or #stroke compared with placebo.
Read more in our #AHA25 coverage: https://bit.ly/4oBNohQ
#CardioSky #MedSky